Glaxo Executive’s Memo Suggested Burying Drug Studies

http://www.bloomberg.com/apps/news?pid=newsarchive&sid=ae8Ie3hNoafw
Authors: Feeley, Jef; Fisk, Margaret
Source: Bloomberg.com
Year: 2009
Company Name: GlaxoSmithKline Plc

[This document has not yet been rated] [You must be signed in as faculty to rate this document]   460 views

Abstract:

GlaxoSmithKline Plc, the world’s second-biggest drugmaker, talked about burying negative studies linking its antidepressant drug Paxil to birth defects, according to a company memo introduced at a trial.

The Philadelphia trial is the first of more than 600 cases alleging that London-based Glaxo knew Paxil caused birth defects and hid those risks to pump up profits.